An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract Cancer

This is an intermediate-size Expanded Access Protocol (EAP) for use of zanidatamab (ZW25) in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced biliary tract cancer (BTC) who are not eligible for other zanidatamab clinical trials, and who in the opinion of the treating oncologist, would potentially benefit from treatment with zanidatamab.

This study is open at the following sites in the UK:

The Princess Alexandra Hospital NHS Trust
Harlow, Essex

UCLH Cancer Institute
London, WC1E 6AG
HCA Healthcare UK

Sponsor: Jazz Pharmaceutical 

For more information, see:

Back to previous page